NASDAQ: FHTX - Foghorn Therapeutics Inc.

Rentabilidade por seis meses: -11.4%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Foghorn Therapeutics Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

mais detalhes
It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2020-10-23
ISIN US3441741077
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://foghorntx.com
Цена ао 6.07
Alteração de preço por dia: -5.3% (5.09)
Alteração de preço por semana: -6.23% (5.14)
Alteração de preço por mês: -38.13% (7.79)
Alteração de preço em 3 meses: -48.5% (9.36)
Mudança de preço em seis meses: -11.4% (5.44)
Mudança de preço por ano: -25.27% (6.45)
Mudança de preço em 3 anos: -75.21% (19.44)
Mudança de preço em 5 anos: 0% (4.82)
Mudança de preço em 10 anos: 0% (4.82)
Mudança de preço desde o início do ano: -48.45% (9.35)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 8.16 1
P/BV -3.61 0
P/E 0 0
EV/EBITDA -2.45 0
Total: 3.88

Eficiência

Nome Significado Nota
ROA, % -34.42 0
ROE, % 127.51 10
Total: 3.33

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.4542 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 7843.02 10
Rentabilidade Ebitda, % 109.33 10
Rentabilidade EPS, % 0.2094 1
Total: 8
Mais detalhes

Data da transação Data de divulgação Insider Tipo Preço Volume Quantidade Compartilhe até, % Compartilhe depois, % Documento
23.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Oferta 10.17 8 716 857 0 0 link
23.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Comprar 3.72 3 188 857 0 0 link
20.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Oferta 10.04 358 990 35756 0 -0.09 link
20.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Comprar 3.72 133 012 35756 0 0.09 link
18.09.2024 20.09.2024 Costa Carlos
Chief People Officer		 Oferta 10.05 116 319 11574 0 -0.03 link
18.09.2024 20.09.2024 Costa Carlos
Chief People Officer		 Comprar 3.72 43 055 11574 0 0.03 link

Instituições Volume Compartilhar, %
Flagship Pioneering Inc. 12674120 29.78
FMR, LLC 2810009 6.6
Raymond James & Associates, Inc. 2068387 4.86
Euclidean Capital LLC 1573761 3.7
Blackrock Inc. 1305868 3.07
Vanguard Group Inc 1025113 2.41
Artal Group S.A. 720720 1.69
Point72 Asset Management, L.P. 540000 1.27
Alphabet Inc. 500901 1.18
Geode Capital Management, LLC 448350 1.05

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
Range Cancer Therapeutics ETF 2.15956 47.24 0.11955
iShares Micro-Cap ETF 0.06408 17.09 1.54048
iShares Russell 2000 Growth ETF 0.01111 38.04 0.6026
Vanguard Russell 2000 ETF 0.01 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
ProShares UltraPro Russell2000 0.00545 89.82 1.47873
ProShares Hedge Replication ETF 0.00149 5.92 1.47892
Avantis U.S. Equity ETF 0.0004 23.04 1.59151
Vanguard Russell 3000 ETF 0 31.87 1.43817



Supervisor Cargo Pagamento Ano de nascimento
Mr. Adrian H. B. Gottschalk President, CEO & Director 784.65k 1976 (49 anos)
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer 572.6k 1965 (60 anos)
Mr. Michael J. LaCascia Chief Legal Officer 565.5k 1965 (60 anos)
Dr. Gerald R. Crabtree M.d. Founder & Member of Scientific Advisory Board N/A
Mr. Saurabh Sewak Ph.D. Vice President of Corporate Development N/A
Mr. Carlos Costa Chief People Officer N/A 1973 (52 ano)
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer 300.16k 1971 (54 ano)
Ms. Karin Hellsvik VP of Corporate Affairs & Investor Relations N/A
Mr. Kristian Humer M.B.A. Chief Financial Officer N/A 1976 (49 anos)
Dr. Anna Rivkin Ph.D. Chief Business Officer

Endereço: United States, Cambridge. MA, 500 Technology Square - abrir no Google Maps, abrir mapas Yandex
Site: https://foghorntx.com